Hangzhou Diagens Biotechnology Co., Ltd. (“Diagens”) has called its first extraordinary general meeting (EGM) of 2026 for 14:00 on 23 July 2026 in Hangzhou to secure shareholder approval for two key items:
1. Expansion of Business Scope • New general-item activities: software development; wholesale and retail of computer software, hardware and auxiliary equipment; sales of electronic and communication products; computer system and integration services; big-data services; data processing and storage support; internet data services; development of basic and application-level artificial-intelligence software; sales of AI hardware; and AI industry application system integration. • New licensed-item activities: Class II value-added telecommunications services and internet information services. • Existing medical-device manufacturing and chemical-product operations remain unchanged.
2. Corresponding Amendments to Articles of Association • The revised Article 15 will incorporate the above additions and clarify that licensed businesses require prior regulatory approval.
Key Meeting and Administrative Details • Record date: 20 July 2026. • Register closure: 20–23 July 2026 (both dates inclusive); share transfers must be lodged by 16:30 on 17 July 2026 with Computershare Hong Kong Investor Services Limited. • Proxy deadline: 14:00 on 22 July 2026. • Voting method: poll, in line with Hong Kong Listing Rules. • No shareholders are required to abstain from voting.
Legal Confirmation Company counsel for Hong Kong and PRC laws confirm the draft amendments comply with Listing Rules and PRC regulations.
Board Recommendation The board unanimously supports the proposed expansion and urges shareholders to vote in favour at the upcoming EGM.
Comments